EpiCure

EpiCure is a Belgian biotechnology company focused on the emerging field of epitranscriptomics to develop novel cancer therapies. A spin-off from the Université Libre de Bruxelles (ULB), the company leverages the research of Professor François Fuks to target RNA-modifying enzymes that drive oncogenic processes. By developing small molecule inhibitors against specific RNA methyltransferases, EpiCure aims to correct epigenetic dysregulation in various solid and liquid tumors. The company's platform integrates deep expertise in RNA epigenetics with drug discovery capabilities to build a pipeline of first-in-class therapeutic candidates.